ArticlePLoS neglected tropical diseases2020
Clinical characteristics and treatment of actinomycetoma in northeast Mexico: A case series.
Article in PLoS neglected tropical diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Case Report: Coral Reef Pathogen Aspergillus sydowii Causing Black Grain Mycetoma.The American journal of tropical medicine and hygiene · 2021Pooled it
- A qPCR identification scheme to detect the most common causative agents of actinomycetoma in Africa.PLoS neglected tropical diseases · 2026Article
- Article
- Mycetoma.PLoS neglected tropical diseases · 2026Review
- A rare presentation of actinomycotic mycetoma of the hand: a case report.BMC infectious diseases · 2026Article
- Surgical Management and Antifungal Therapy for Extensive Eumycetoma of the Right Foot: A Case Report from Resource Limited Settings.International medical case reports journal · 2026Article
- Medical and health students' insights into mycetoma: A survey-based study on knowledge and clinical practices.PLoS neglected tropical diseases · 2025Article
- Eumycetoma: pathogenesis, current treatments, and the search for new drugs.Applied microbiology and biotechnology · 2025Review
- Actinomadura welshii sp. nov., a New Mycetoma Agent in Mexico.PLoS neglected tropical diseases · 2025Article
- Comprehensive management of actinomycetoma in a young male: A case report from Somalia.IDCases · 2025Article
- An updated list of eumycetoma causative agents and their differences in grain formation and treatment response.Clinical microbiology reviews · 2024Review
- Diagnostic capacities and treatment practices on implantation mycoses: Results from the 2022 WHO global online survey.PLoS neglected tropical diseases · 2023Article
- A scoping review of mycetoma profile in Egypt: revisiting the global endemicity map.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2023Article
- Genetic variability of the 16S rRNA gene of Nocardia brasiliensis, the most common causative agent of actinomycetoma in Latin America and the Caribbean.Revista do Instituto de Medicina Tropical de Sao Paulo · 2023Article
- Mycetoma: Development of Diagnosis and Treatment.Journal of fungi (Basel, Switzerland) · 2022Review
- Mycetoma by Actinomadura madurae in the central nervous system: Renal transplant receptor disease.Clinical case reports · 2022Article
- Climate, soil type, and geographic distribution of actinomycetoma cases in Northeast Mexico: A cross-sectional study.PloS one · 2020Article
- Actinomycetoma byIndian dermatology online journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycetoma is a neglected tropical disease characterized by nodules, scars, abscesses, and fistulae that drain serous or purulent material containing the etiological agent. Mycetoma may be caused by true fungi (eumycetoma) or filamentous aerobic bacteria (actinomycetoma). Mycetoma is more frequent in the so-called mycetoma belt (latitude 15° south and 30° north around the Tropic of Cancer), especially in Sudan, Nigeria, Somalia, India, Mexico, and Venezuela. The introduction of new antibiotics with fewer side effects, broader susceptibility profiles, and different administration routes has made information on actinomycetoma treatment and outcomes necessary. The objective of this report was to provide an update on clinical, therapeutic, and outcome data for patients with actinomycetoma attending a reference center in northeast Mexico. METHODOLOGY/PRINCIPAL
findingsThis was a retrospective, cross-sectional, descriptive study of 31 patients (male to female ratio 3.4:1) diagnosed with actinomycetoma by direct grain examination, histopathology, culture, or serology from January 2009 to September 2018. Most lesions were caused by Nocardia brasiliensis (83.9%) followed by Actinomadura madurae (12.9%) and Actinomadura pelletieri (3.2%). About 50% of patients had bone involvement, and the right leg was the most commonly affected region in 38.7% of cases. Farmers/agriculture workers were most commonly affected, representing 41.9% of patients. The most commonly used treatment regimen was the Welsh regimen (35.5% of cases), a combination of trimethoprim/sulfamethoxazole (TMP/SMX) plus amikacin, which had a 90% cure rate, followed by TMP/SMX plus amoxicillin/clavulanic acid in 19.4% of cases with a cure rate of 100%. In our setting, 28 (90.3%) patients were completely cured and three (9.7%) were lost to follow-up. Four patients required multiple antibiotic regimens due to recurrences and adverse effects. CONCLUSIONS/SIGNIFICANCE: In our sample, actinomycetoma was predominantly caused by N. brasiliensis. Most cases responded well to therapy with a combination of TMP/SMX with amikacin or TMP/SMX and amoxicillin/clavulanic acid. Four patients required multiple antibiotics and intrahospital care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.